HFpEF Cardiac Fibrosis: TAC, AngII, ISO, Multi-hit Selection
Select the right HFpEF model (TAC, AngII, Multi-hit) for diastolic dysfunction and fibrosis, with E/e echocardiography and Azan staining correlation.
Lead: A frequently raised issue in cardiovascular drug development is the gap between MI (myocardial infarction) model results and HFpEF clinical trial readouts. HFpEF preserves ejection fraction while suffering from diastolic dysfunction, with cardiac fibrosis recognized as a major therapeutic target among several (alongside endothelial dysfunction, metabolic comorbidity, and microvascular inflammation) in this multi-factorial syndrome[ref-paulus]. This guide delivers a targeted selection of HFpEF models and an evaluation framework combining E/e' echocardiography with Azan staining for functional‑structural correlation, tailored for Cardio‑Renal investigators.
Key Takeaways
- 【Shift】Why you must move from MI models to HFpEF models
- 【Selection】Decision flowchart for TAC, AngII, ISO, and Multi-hit models
- 【Evaluation】How to prove drug efficacy by correlating E/e' (function) with Azan CVF (structure)
1. Why "Fibrosis" is a Major Target in HFpEF
1-1. The Critical Difference from MI Models
| Feature | MI (Myocardial Infarction) Model | HFpEF Model |
|---|---|---|
| Primary Pathology | Myocyte death → Pump failure | Diastolic dysfunction + Interstitial fibrosis |
| EF | ❌ Reduced (HFrEF) | ✅ Preserved |
| Fibrosis Type | Replacement (Scar) | Reactive Interstitial |
| Drug Targets | β-blockers, ACE-i (Established) | Unmet Medical Need |
The fibrosis in HFpEF is NOT the scar tissue replacing dead myocytes (as in MI). It's reactive interstitial fibrosis, where collagen accumulates between living cardiomyocytes, increasing ventricular stiffness and elevating filling pressure (leading to pulmonary congestion).
1-2. The Inflammation-Fibrosis Axis: HFpEF as a Systemic Disease
According to the Paulus-Tschöpe paradigm, HFpEF is not just a cardiac disease.
1-3. The Cardio-Renal Axis: Toxins from the Kidney
[!IMPORTANT] Cardiotoxicity of Indoxyl Sulfate (IS) The uremic toxin IS, which accumulates in CKD patients, activates the AhR (Aryl Hydrocarbon Receptor) in cardiac fibroblasts, amplifying TGF-β signaling and directly promoting cardiac fibrosis. Treating the kidney to treat the heart—this is the essence of Cardio-Renal drug discovery.
2. "Beyond MI": Strategic Selection of HFpEF Models
2-1. TAC (Transverse Aortic Constriction): A Workhorse Model for Mechanical Stress
Creates a stenosis in the aortic arch to apply pressure overload to the left ventricle. Mimics aortic stenosis or severe hypertension.
Fibrosis Phases and the Therapeutic Window:
| Phase | Post-op | Pathology | Drug Study Suitability |
|---|---|---|---|
| Compensated | 1-2 wks | Concentric hypertrophy, EF preserved | △ Too early |
| Transition | 4-8 wks | Interstitial fibrosis, Diastolic dysfunction | ✅ Optimal |
| Decompensated | 8+ wks | Dilation, EF decline (HFrEF-like) | ❌ Too late (Burn-out) |
[!TIP] Needle Gauge Outcomes Are Protocol-Dependent
- 27G (0.41 mm): higher stenosis severity → reported with higher acute mortality and acute HF; often considered unsuitable for long-term HFpEF observation. Reported mortality rates vary widely across institutions.
- 25G (0.51 mm): milder stenosis → many institutional protocols select 25G for long-term observation studies (institution-reported mortality varies). Mortality percentages and HFpEF suitability depend strongly on C57BL/6 substrain, anesthesia / post-operative care, and surgeon experience. Pre-specify the gauge choice from in-house pilot data, not from a single literature number.
2-2. AngII Infusion Model: Validating Inflammation & RAAS
Continuous subcutaneous infusion of Angiotensin II via osmotic pump. Induces hypertension plus perivascular-dominant fibrosis and inflammation.
- Hallmark: "Onion-skin" perivascular fibrosis → spreads to interstitium
- Strength: Co-induces renal injury and perivascular fibrosis, making it one of the commonly used models for Cardio-Renal research (whether it is "ideal" depends on MoA and biomarker plan)[ref-ahr-angii]
- Subpressor dose: Even doses that don't raise BP can induce fibrotic signaling directly
2-3. ISO (Isoproterenol) Model: Short-Term Cardiac Fibrosis Induction
Mimics sympathetic overactivation. High doses cause myocyte necrosis and replacement fibrosis, which does not recapitulate the reactive-interstitial / EF-preserved pathology of HFpEF. ISO is therefore best framed as a short-term cardiac fibrosis induction model — useful for anti-fibrotic screening or MoA exploration in 1-2 weeks, but not suitable as a stand-in for HFpEF phenotypes such as diastolic dysfunction or exercise intolerance[ref-iso].
2-4. Multi-hit (L-NAME + HFD) Model: A Leading Contemporary HFpEF Model
[!NOTE] The L-NAME + HFD multi-hit HFpEF model published by Schiattarella et al. in Nature 2019[ref-schiattarella]. Recent HFpEF animal-model reviews position it as one of the leading contemporary models for metabolic HFpEF, not as a formal "guideline gold standard"[ref-hfpef-models-review][ref-metabolic-hfpef].
- L-NAME (NOS inhibitor) induces hypertension and endothelial dysfunction.
- HFD (High-Fat Diet) induces obesity and metabolic abnormalities.
Combining these two reproduces the principal HFpEF phenotype: "Preserved EF + Reduced exercise tolerance + Pulmonary congestion + Fibrosis"[ref-schiattarella]. For metabolic HFpEF (obesity / diabetes comorbidity), this is one of the most widely used multi-hit models in current practice.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
3. The 30-Second Model Selection Guide
3-1. Comparison Matrix
| Feature | TAC (25G) | AngII Infusion | ISO | L-NAME + HFD |
|---|---|---|---|---|
| Main Driver | Pressure Overload | RAAS / Inflammation | Sympathetic Toxicity | Metabolic + Endothelial |
| Fibrosis | Interstitial + Perivascular | Perivascular-dominant | Replacement + Interstitial | Diffuse Interstitial |
| LVEF | ✅ Preserved (up to 8 wks) | ✅ Preserved | ⚠️ Mild reduction possible | ✅ Preserved |
| Hypertension | No (Local load) | ✅ Yes | ❌ No | ✅ Yes |
| Renal Damage | Mild | ✅ Moderate-High | Mild | Moderate |
| Best For | Anti-hypertrophy, Mechanotransduction | Cardio-Renal | Short-term Screening | Metabolic HFpEF |
3-2. Selection Flowchart by MoA
Where does your drug hit?
4. The Heart of Evaluation: E/e' × Azan Staining Correlation
Showing "fibrosis decreased" isn't enough for publication. You must prove it translated into functional improvement.
4-1. E/e': A Key Index for Diastolic Function
| Index | Meaning | Change in HFpEF |
|---|---|---|
| E wave | Early diastolic inflow velocity | Increases (LA pressure ↑) |
| e' wave | Mitral annulus relaxation velocity | Decreases (Stiff myocardium) |
| E/e' | Surrogate for LV Filling Pressure | Increases. In adult human echocardiography, E/e' >15 is a clinical threshold for diastolic dysfunction; in mouse studies it should be interpreted as a group-comparison / change-from-baseline metric rather than an absolute cutoff, given species and acquisition differences. |
Tips for Mouse Echocardiography:
- Probe: 30-40 MHz high-frequency (e.g., Vevo 3100)
- Heart Rate: Maintain at 450-500 bpm (for E/A wave separation)
- Measurement Site: Septal mitral annulus
4-2. Azan Staining: Best Practice for Fibrosis Quantification
[!TIP] Azan staining as a practical staining preference Some labs prefer Azan staining because it can render collagen a deep blue with high contrast against the myocardium, which can help detect fine, reticular fibrosis characteristic of HFpEF and supports automated image analysis. This is a practical staining preference, not a universal best practice — outcomes depend on staining protocol, section thickness, and analysis pipeline, and Masson's Trichrome remains a valid alternative when standardized appropriately.
Quantification Protocol (CVF: Collagen Volume Fraction):
- Section thickness: 4-5 µm (thicker → overestimation)
- Use ImageJ/QuPath for blue component thresholding
- CVF (%) = Blue Area / Total Tissue Area × 100
- Separately calculate Perivascular vs. Interstitial CVF
4-3. "Structure-Function Correlation" is the Key to Proof
The ideal data story:
"In the drug-treated group, CVF by Azan staining was significantly reduced compared to Vehicle (structural improvement), AND this change correlated with a reduction in E/e' (functional improvement)."
By demonstrating that reduced fibrosis directly translates to improved diastolic function, you prove that the drug effect has clinical significance, not just a histological change.
5. Conclusion: The Winning Strategy for Cardio-Renal Researchers
Success in HFpEF drug discovery hinges on three points:
- Move Beyond MI: The essence of HFpEF is "Diastolic Dysfunction + Fibrosis." Use TAC 25G, AngII, or Multi-hit based on your objective.
- E/e' × Azan Staining: Correlate function (diastolic) with structure (fibrosis) to prove the clinical significance of your drug effect.
- Cardio-Renal Perspective: Recognize that kidney-derived factors (Indoxyl Sulfate) and immune mediators (Galectin-3) drive cardiac fibrosis. Build systemic, not just cardiac-local, intervention strategies.
Related Articles
- Fibrosis Evaluation Basics
- Renal Model Integration
References
HFpEF Pathophysiology & Models
- Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17(9):559-573. PubMed PMID 32139904
- Schiattarella GG, Altamirano F, Tong D, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019;568(7752):351-356. PubMed PMID 30971818 / DOI:
10.1038/s41586-019-1100-z— original L-NAME + HFD multi-hit HFpEF mouse model - Glezeva N, et al. Exaggerated inflammation and monocytosis associate with diastolic dysfunction in HFpEF. J Mol Cell Cardiol. 2015;80:106-116. PubMed PMID 25643839
- Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-271. PubMed PMID 23684677 / DOI:
10.1016/j.jacc.2013.02.092 - Conceição G, Heinonen I, Lourenço AP, Duncker DJ, Falcão-Pires I. Animal models of heart failure with preserved ejection fraction. Neth Heart J. 2016;24(4):275-286. PubMed PMID 26936157
- Withaar C, Lam CSP, Schiattarella GG, de Boer RA, Meems LMG. Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. Eur Heart J. 2022. PubMed PMID 35592030
Microvascular / Endothelial Dysfunction
- Shah SJ, Lam CSP, Svedlund S, et al. Prevalence and correlates of coronary microvascular dysfunction in HFpEF: PROMIS-HFpEF. Eur Heart J. 2018;39(37):3439-3450. PubMed PMID 30165580 / DOI:
10.1093/eurheartj/ehy531 - Endothelial dysfunction perspectives on HFpEF. PubMed PMID 35874523
ISO / Cardio-Renal / AhR & Indoxyl Sulfate
- Costa S, et al. Isoproterenol-induced myocardial fibrosis review. Animal Model Exp Med. 2024. PubMed PMID 39690876 / DOI:
10.1002/ame2.12496 - Yisireyili M, et al. Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats. Life Sci. 2013. PubMed PMID 23702423 / DOI:
10.1016/j.lfs.2013.05.008 - Indoxyl sulfate activation of cardiac fibroblasts via AhR/NRF2 signaling. J Cell Mol Med. 2024. PubMed PMID 38506079 / DOI:
10.1111/jcmm.18192 - AhR signaling in AngII-induced cardiac fibrosis. Arch Toxicol. 2019. PubMed PMID 31016362 / DOI:
10.1007/s00204-019-02446-1